Nucleic Acid Amplification Testing

Nucleic Acid Amplification Testing Market Outlook

The global nucleic acid amplification testing (NAAT) market was valued at approximately USD 4.5 billion in 2023 and is projected to reach USD 10.2 billion by 2035, growing at a CAGR of around 10.8% during the forecast period from 2025 to 2035. This significant growth can be attributed to the increasing prevalence of infectious diseases, the rising demand for rapid diagnostic tests, and advancements in amplification technologies that enhance the accuracy and efficiency of testing methodologies. Furthermore, factors such as the growing focus on personalized medicine and genetic testing, alongside the ongoing emphasis on preventive healthcare, are expected to fuel market expansion. The COVID-19 pandemic has also accelerated the adoption and innovation of nucleic acid amplification tests across various healthcare sectors, resulting in increased investments and research activities.

Growth Factor of the Market

The nucleic acid amplification testing market is expected to grow significantly due to several key factors. The increasing incidence of infectious diseases, such as COVID-19, tuberculosis, and sexually transmitted infections, has created a strong demand for rapid and accurate diagnostic tests. Additionally, advancements in molecular diagnostic technologies, including the development of more sophisticated and user-friendly amplification techniques, are driving market growth. Furthermore, the rise of personalized medicine has led to an increased focus on genetic testing, as healthcare providers seek to tailor treatments based on individual genetic profiles. Regulatory approvals for novel NAAT devices and tests are also contributing to market expansion by facilitating easier access for healthcare providers and patients. Lastly, the growing awareness of the benefits of early diagnosis and treatment is pushing healthcare systems to invest more in nucleic acid amplification technologies.

Key Highlights of the Market

• The NAAT market is anticipated to be driven by a CAGR of 10.8% from 2025 to 2035.
• Growing focus on personalized medicine is promoting an increase in genetic testing applications.
• The COVID-19 pandemic highlighted the necessity for rapid diagnostic testing, boosting market growth.
• Technological advancements are enabling more accurate and efficient nucleic acid amplification methods.
• The rising prevalence of infectious diseases is creating increasing demand for nucleic acid testing solutions.

By Product Type

PCR:

Polymerase Chain Reaction (PCR) remains one of the most widely used methods within the nucleic acid amplification testing market. The technique enables the amplification of specific DNA sequences, making it invaluable in various applications, including infectious disease testing, genetic research, and forensic analysis. PCR's ability to produce millions of copies of a target DNA sequence in just a few hours has made it a cornerstone in laboratory diagnostics. As the demand for rapid and accurate testing continues to grow, innovations in PCR technology, such as real-time PCR and digital PCR, are expected to enhance precision and speed, further solidifying PCR's dominance in the market.

Loop-mediated Isothermal Amplification (LAMP):

Loop-mediated Isothermal Amplification (LAMP) is gaining traction as an alternative to traditional PCR methods due to its simplicity and efficiency. Unlike PCR, LAMP can be performed at a constant temperature, eliminating the need for complex thermocycling equipment. This characteristic makes LAMP particularly suited for point-of-care testing and low-resource settings. The method’s rapid amplification process, which can yield results in less than an hour, is appealing for applications in infectious disease diagnosis, particularly in remote areas where timely interventions are critical. As healthcare systems continue to seek innovative, accessible diagnostic tools, LAMP is expected to become a substantial player in the NAAT market.

Transcription-mediated Amplification (TMA):

Transcription-mediated Amplification (TMA) is another important method in the nucleic acid amplification testing segment. TMA amplifies RNA targets by first converting them to complementary DNA (cDNA) and then generating additional RNA copies through a unique transcription process. This technique is particularly useful for diagnosing viral infections, as many viruses present RNA as their genetic material. TMA's inherent sensitivity and specificity make it a valuable tool in clinical laboratories, especially for testing pathogens such as hepatitis C and HIV. The increasing adoption of TMA in clinical settings is expected to fuel its growth as part of the broader NAAT market.

Nucleic Acid Sequence-based Amplification (NASBA):

Nucleic Acid Sequence-based Amplification (NASBA) is a specialized amplification technique designed primarily for RNA targets. It utilizes a unique enzymatic process, resulting in the preferential amplification of RNA sequences without the need to convert them into DNA. NASBA's sensitivity and specificity make it particularly beneficial for the early detection of viral infections, especially in cases where quick diagnostic action is necessary. As the focus on viral diagnostics intensifies, particularly in light of recent global health crises, NASBA is anticipated to find increased application across laboratories and healthcare facilities, contributing to the overall growth of the NAAT market.

Helicase-dependent Amplification (HDA):

Helicase-dependent Amplification (HDA) is an innovative method that allows for the amplification of DNA at a constant temperature, similar to LAMP. HDA employs helicase enzymes to separate DNA strands, allowing for the amplification process to occur. This method circumvents the need for high-temperature cycling, making it a user-friendly option for laboratories. The reduced equipment requirements mean that HDA is particularly appealing for resource-limited settings. HDA's ability to produce results quickly and efficiently is expected to enhance its adoption in various diagnostics applications, thus contributing to the overall expansion of the nucleic acid amplification testing market.

By mediated Isothermal Amplification

Recombinase Polymerase Amplification (RPA):

Recombinase Polymerase Amplification (RPA) is a isothermal amplification technique that leverages recombinase enzymes to facilitate the annealing of primers to target nucleic acids. Its simplicity and rapidity make RPA particularly appealing for field testing applications. RPA can provide results in as little as 20 minutes, making it an efficient option for time-sensitive diagnostics. The technique's compatibility with various detection methods, including fluorescent and lateral flow assays, further enhances its utility across clinical and point-of-care testing settings. As the demand for rapid and portable diagnostic solutions continues to rise, RPA is expected to play a pivotal role within the NAAT market.

By mediated Amplification

Single-primer Amplification:

Single-primer amplification is a unique method that utilizes a single primer to initiate the amplification of nucleic acids. While this technique is not as commonly used as traditional amplification methods, it presents an interesting alternative for specific applications, particularly in scenarios where traditional methods may be cumbersome. The method's ability to simplify the amplification process can lead to significant time and resource savings, appealing to laboratories that require rapid results. As research into single-primer amplification techniques progresses, it may find niche applications in the broader context of nucleic acid amplification testing.

By based Amplification

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based amplification:

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a groundbreaking method for nucleic acid amplification that combines genome editing capabilities with diagnostic applications. CRISPR-based amplification techniques utilize the CRISPR-Cas system to selectively target and amplify specific nucleic acid sequences. This method offers unprecedented sensitivity and specificity, allowing for the detection of low-abundance targets that traditional amplification methods might miss. As CRISPR technology continues to evolve, its integration into nucleic acid amplification testing is expected to revolutionize diagnostics, particularly in the realm of infectious disease detection and genetic testing.

By dependent Amplification

Reverse Transcription PCR (RT-PCR):

Reverse Transcription PCR (RT-PCR) is a widely used method for amplifying RNA sequences by first converting them into complementary DNA (cDNA) using reverse transcriptase enzymes. This technique has gained immense popularity, especially in the context of viral diagnostics, where RNA viruses are prevalent. RT-PCR is essential for detecting pathogens like SARS-CoV-2, the virus responsible for COVID-19, highlighting its critical role in public health responses. The ability of RT-PCR to provide rapid and accurate results positions it as a key player in the nucleic acid amplification testing market, particularly in the wake of global health crises.

By Application

Infectious Disease Testing:

The application of nucleic acid amplification testing for infectious disease detection is one of the primary drivers of market growth. By enabling rapid and accurate identification of pathogens, NAAT offers healthcare professionals valuable tools for timely diagnosis and treatment. The increasing incidence of infectious diseases, including COVID-19, tuberculosis, and sexually transmitted infections, has underscored the need for efficient testing solutions. Furthermore, the ability to detect pathogens at low concentrations enhances the effectiveness of public health measures, particularly in outbreak scenarios. Consequently, as the global burden of infectious diseases continues to rise, the demand for NAAT in this application area is expected to flourish.

Cancer Diagnosis:

In the realm of oncology, nucleic acid amplification testing is gaining traction for cancer diagnosis and monitoring. NAAT enables the detection of specific genetic mutations and alterations associated with various types of cancer, facilitating personalized treatment approaches. As the understanding of cancer genomics expands, clinicians are increasingly relying on NAAT to identify biomarkers that predict patient responses to targeted therapies. The growing emphasis on precision medicine is driving demand for these advanced diagnostic tools, as cancer care shifts toward more individualized treatment strategies. The expansion of the NAAT market in cancer diagnosis is expected to continue as research and clinical applications evolve.

Genetic Testing:

Genetic testing is another significant application of nucleic acid amplification testing, allowing for the detection of inherited genetic disorders and predispositions. NAAT plays a crucial role in identifying mutations in genes associated with conditions such as cystic fibrosis, sickle cell disease, and various hereditary cancers. As genetic testing becomes more mainstream, driven by increasing awareness and advancements in genomic technologies, the demand for NAAT in this application area is likely to grow. Furthermore, the integration of genetic testing in routine healthcare practices, coupled with the rising interest in personalized medicine, is expected to propel the nucleic acid amplification testing market forward.

Paternity Testing:

Paternity testing is a specialized area where nucleic acid amplification testing is utilized to establish biological relationships. NAAT's high sensitivity and specificity allow for the accurate analysis of genetic markers that indicate parentage. Increasing public interest in genetic relationships, coupled with the growing availability of direct-to-consumer genetic testing services, has created a burgeoning market for paternity testing. As societal norms continue to evolve, the demand for accurate and reliable paternity testing is anticipated to rise, further driving the growth of the nucleic acid amplification testing landscape.

By Distribution Channel

Hospitals & Clinics:

Hospitals and clinics remain the primary distribution channel for nucleic acid amplification testing. These facilities serve as the frontline for patient diagnostics, and the growing emphasis on rapid and accurate testing has led to increased investments in NAAT technologies. The ability to provide timely results can significantly impact patient management and treatment outcomes, particularly in emergency settings. Additionally, as healthcare systems shift towards integrated care models, the demand for efficient diagnostic solutions within hospitals and clinics is expected to increase. Consequently, this distribution channel is poised to witness substantial growth in the NAAT market.

Diagnostic Laboratories:

Diagnostic laboratories play a critical role in the distribution of nucleic acid amplification testing, serving as specialized facilities for conducting a wide range of tests. The increasing complexity of testing requirements and the demand for accurate results are driving laboratories to adopt advanced NAAT technologies. These facilities benefit from economies of scale, allowing them to offer more comprehensive testing services. Moreover, as the landscape of laboratory diagnostics continues to evolve, partnerships between diagnostic manufacturers and laboratories are likely to become more prevalent, facilitating the adoption of innovative NAAT solutions and enhancing market growth.

Research Institutes:

Research institutes are vital players in the nucleic acid amplification testing market, contributing to the development of new amplification methods and applications. Their focus on advancing scientific knowledge and technological innovation drives the evolution of NAAT technologies. Collaborations between research institutions and commercial entities can result in the accelerated introduction of cutting-edge diagnostic tools to the market. As research into genomics and molecular biology continues to advance, the contributions of research institutes in the field of nucleic acid amplification testing are expected to catalyze market growth and drive innovation.

By Target Type

DNA:

Nucleic acid amplification testing targeting DNA is a crucial segment of the market, as it covers a wide array of applications, including infectious disease diagnostics and genetic testing. DNA amplification methods, such as PCR, enable the identification of specific genetic sequences with high sensitivity and specificity. The increasing focus on personalized medicine and the need for accurate genetic testing are driving the demand for DNA-based NAAT solutions. Furthermore, advancements in DNA amplification technologies are expected to enhance the accuracy and efficiency of testing, contributing to the ongoing growth of the nucleic acid amplification testing market.

RNA:

RNA is another critical target type in the nucleic acid amplification testing market, particularly for the detection of RNA viruses and other pathogens. Amplification methods such as RT-PCR and NASBA are specifically designed to address RNA targets, making them indispensable in the field of infectious disease diagnostics. The growing prevalence of RNA viruses, exemplified by the COVID-19 pandemic, has heightened the demand for RNA-targeted NAAT solutions. Additionally, as the understanding of RNA's role in various diseases expands, the market for RNA amplification technologies is expected to flourish, further driving the growth of the nucleic acid amplification testing landscape.

By Region

The regional analysis of the nucleic acid amplification testing market reveals significant growth opportunities across various geographies. North America holds a substantial share of the market, owing to the presence of advanced healthcare infrastructure, high levels of investment in research and development, and a growing demand for rapid diagnostic solutions. The region is anticipated to grow at a CAGR of approximately 11.2% during the forecast period, driven by the increasing prevalence of infectious diseases and the ongoing innovation in NAAT technologies. Furthermore, the adoption of personalized medicine and increasing awareness about genetic testing in North America are expected to bolster the market.

Europe is another key region in the nucleic acid amplification testing market, driven by a well-established healthcare system and a growing emphasis on molecular diagnostics. The European market benefits from collaborative efforts among healthcare providers, research institutions, and regulatory bodies, facilitating the rapid development and implementation of NAAT solutions. Additionally, the rising incidence of infectious diseases and cancer in Europe is fostering demand for advanced diagnostic tools. As the focus on precision medicine and preventive healthcare intensifies, the nucleic acid amplification testing market in Europe is anticipated to witness steady growth, aligning with the global upward trend.

Opportunities

The nucleic acid amplification testing market is ripe with opportunities, particularly in the realm of technological advancements and the growing emphasis on personalized medicine. The continuous development of innovative amplification technologies, such as CRISPR-based diagnostics and advanced isothermal amplification methods, is expected to drive market growth. These advancements promise to enhance the sensitivity, specificity, and speed of nucleic acid tests, making them more accessible for a wider range of applications. Furthermore, the increasing integration of NAAT in routine healthcare practices presents opportunities for companies to introduce novel testing solutions tailored to meet diverse diagnostic needs. As healthcare providers seek to improve patient outcomes through timely and accurate diagnostics, the market for nucleic acid amplification testing is well-positioned for substantial growth.

Moreover, the expansion of point-of-care testing options is another significant opportunity within the NAAT market. The rising demand for rapid diagnostic solutions in remote and resource-limited settings is driving innovation in portable and user-friendly testing devices. The ability to perform nucleic acid tests at the point of care not only enhances patient management but also contributes to more effective public health responses to infectious disease outbreaks. As manufacturers develop and commercialize point-of-care NAAT solutions, the market is likely to witness increased adoption, further propelling growth and transforming the diagnostics landscape.

Threats

Despite the promising growth prospects, the nucleic acid amplification testing market faces several threats that could impact its trajectory. One significant concern is the potential for regulatory changes and stringent approval processes for new diagnostic tests. As governments and regulatory bodies impose stricter guidelines to ensure the safety and effectiveness of medical devices, companies may experience delays in bringing innovative NAAT solutions to market. Moreover, the evolving landscape of molecular diagnostics may create challenges for traditional methods, prompting a need for continuous adaptation and improvement in existing technologies. Companies that are unable to keep pace with these changes may risk losing their competitive edge in a rapidly evolving market.

Additionally, the increasing prevalence of counterfeit and substandard diagnostic tests poses a significant threat to the nucleic acid amplification testing market. The emergence of unregulated products can undermine consumer trust and adversely affect the reputation of established manufacturers. Public health initiatives aimed at preventing the spread of misinformation and promoting accurate diagnostics must be prioritized to safeguard the integrity of the market. Furthermore, the potential for reduced funding and investment in research and development due to economic fluctuations could hinder innovation and slow the advancement of nucleic acid amplification technologies.

Competitor Outlook

• Thermo Fisher Scientific
• Abbott Laboratories
• Roche Diagnostics
• Qiagen N.V.
• bioMérieux
• PerkinElmer, Inc.
• Agilent Technologies
• BD (Becton, Dickinson and Company)
• Danaher Corporation
• Hologic, Inc.
• Genomatix Software GmbH
• Sysmex Corporation
• Myriad Genetics, Inc.
• Seegene Inc.
• Meridian Bioscience, Inc.

The overall competitive landscape of the nucleic acid amplification testing market is characterized by a mix of established players and emerging companies striving to innovate and capture market share. Major companies are increasingly focusing on strategic partnerships, acquisitions, and collaborations to enhance their capabilities and expand their product portfolios. The competitive environment is also shaped by ongoing research and development efforts aimed at improving existing amplification technologies and developing novel diagnostic solutions. As a result, the market is witnessing a wave of innovation, with companies racing to introduce more efficient and accurate testing methodologies that cater to the evolving needs of healthcare providers and patients alike.

Thermo Fisher Scientific is a prominent player in the nucleic acid amplification testing market, known for its extensive range of molecular diagnostics solutions, including PCR and qPCR platforms. The company's strong focus on research and development enables it to pioneer innovative technologies that cater to diverse diagnostic needs. Abbott Laboratories is another key player, offering a portfolio of rapid diagnostic tests that leverage nucleic acid amplification techniques for timely and accurate results. The company's commitment to advancing point-of-care testing is expected to bolster its position in the NAAT market.

Roche Diagnostics stands out with its comprehensive diagnostic offerings, including advanced PCR technologies and automation solutions designed to streamline laboratory workflows. The company's continuous investment in molecular diagnostics research enables it to maintain a competitive edge in the nucleic acid amplification testing sector. Qiagen N.V. is also a significant contender, focusing on developing sample preparation and amplification technologies that cater to various applications, including infectious disease diagnostics and cancer detection. As these key players continue to innovate and expand their offerings, they are likely to play pivotal roles in shaping the future of the nucleic acid amplification testing market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Qiagen N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Seegene Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hologic, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 PerkinElmer, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 bioMérieux
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sysmex Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Danaher Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Agilent Technologies
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Myriad Genetics, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Genomatix Software GmbH
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Meridian Bioscience, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Nucleic Acid Amplification Testing Market, By Application
    • 6.1.1 Infectious Disease Testing
    • 6.1.2 Cancer Diagnosis
    • 6.1.3 Genetic Testing
    • 6.1.4 Paternity Testing
    • 6.1.5 Others
  • 6.2 Nucleic Acid Amplification Testing Market, By Distribution Channel
    • 6.2.1 Hospitals & Clinics
    • 6.2.2 Diagnostic Laboratories
    • 6.2.3 Research Institutes
    • 6.2.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Nucleic Acid Amplification Testing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Nucleic Acid Amplification Testing market is categorized based on

By Application

• Infectious Disease Testing
• Cancer Diagnosis
• Genetic Testing
• Paternity Testing
• Others

By Distribution Channel

• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Abbott Laboratories
• Roche Diagnostics
• Qiagen N.V.
• bioMérieux
• PerkinElmer, Inc.
• Agilent Technologies
• BD (Becton, Dickinson and Company)
• Danaher Corporation
• Hologic, Inc.
• Genomatix Software GmbH
• Sysmex Corporation
• Myriad Genetics, Inc.
• Seegene Inc.
• Meridian Bioscience, Inc.